Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
5.14
+0.37 (7.76%)
Nov 13, 2026, 4:00 PM EST - Market closed
Impact BioMedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.04 | 0.03 | - | - | 0.05 | - | |
Revenue Growth | 52.00% | - | - | - | - | - |
Cost of Revenue | 0.43 | 0.42 | - | - | - | - |
Gross Profit | -0.39 | -0.39 | - | - | 0.05 | - |
Selling, General & Admin | 2.72 | 1.98 | 1.83 | 1.1 | 1.12 | 0.99 |
Research & Development | 0.27 | 0.34 | 0.28 | 1.69 | 1.23 | 1.08 |
Other Operating Expenses | 0.28 | 0.42 | 0.17 | 0.12 | - | - |
Operating Expenses | 4.4 | 3.88 | 3.4 | 4.03 | 3.45 | 3.19 |
Operating Income | -4.8 | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 |
Interest Expense | - | -0.79 | -1.07 | -0.44 | -0.46 | -0.3 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.17 |
Other Non Operating Income (Expenses) | 3.82 | -9.39 | 5.07 | 0.05 | 0.07 | 0.08 |
EBT Excluding Unusual Items | -0.96 | -14.44 | 0.62 | -4.41 | -3.78 | -3.24 |
Impairment of Goodwill | - | - | -25.09 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -4.1 | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | - | - | - | - |
Asset Writedown | - | - | -0.26 | - | - | - |
Pretax Income | -0.97 | -14.45 | -24.74 | -4.41 | -7.88 | -3.24 |
Income Tax Expense | -2.58 | -2.58 | 0.03 | - | -0.62 | -1.4 |
Earnings From Continuing Operations | 1.61 | -11.87 | -24.77 | -4.41 | -7.26 | -1.85 |
Minority Interest in Earnings | 0.01 | 0.03 | 0.06 | 0.07 | 0.2 | 0.55 |
Net Income | 1.61 | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 |
Net Income to Common | 1.61 | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 8 | 3 | 1 | 5 | 6 | 6 |
Shares Outstanding (Diluted) | 8 | 3 | 1 | 5 | 6 | 6 |
Shares Change | 761.87% | 193.30% | -82.14% | -14.54% | - | - |
EPS (Basic) | 0.20 | -4.74 | -28.99 | -0.91 | -1.26 | -0.23 |
EPS (Diluted) | 0.18 | -4.80 | -29.03 | -0.91 | -1.26 | -0.23 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.12 | -1.89 | -2.85 | -2.87 | -2.52 | -2.03 |
Free Cash Flow Per Share | 0.01 | -0.76 | -3.35 | -0.60 | -0.45 | -0.36 |
Gross Margin | - | - | - | - | 100.00% | - |
Operating Margin | -12621.05% | -13343.75% | - | - | -6808.00% | - |
Profit Margin | 4247.37% | -36993.75% | - | - | -14102.00% | - |
Free Cash Flow Margin | 305.26% | -5906.25% | - | - | -5036.00% | - |
EBITDA | -4.23 | -3.13 | -3.39 | -4.02 | -2.29 | -2.07 |
D&A For EBITDA | 0.57 | 1.15 | 0.01 | 0.01 | 1.11 | 1.11 |
EBIT | -4.8 | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 |
Revenue as Reported | 0.04 | 0.03 | - | - | - | - |